Literature DB >> 30241913

Manual lymph drainage may not have a preventive effect on the development of breast cancer-related lymphoedema in the long term: a randomised trial.

Nele Devoogdt1, Inge Geraerts2, Marijke Van Kampen2, Tessa De Vrieze2, Lore Vos2, Patrick Neven3, Ignace Vergote4, Marie-Rose Christiaens3, Sarah Thomis5, An De Groef2.   

Abstract

QUESTION: What are the short-term and long-term preventive effects of manual lymph drainage (MLD), when used in addition to information and exercise therapy, on the development of lymphoedema after axillary dissection for breast cancer?
DESIGN: Randomised controlled trial with concealed allocation, blinded assessors and intention-to-treat analysis. PARTICIPANTS: Adults undergoing unilateral dissection for breast cancer were recruited, with 79 allocated to the experimental group and 81 to the control group. INTERVENTION: The experimental group received guidelines about prevention of lymphoedema, exercise therapy and MLD. The control group received the same guidelines and exercise therapy, but no MLD. The interventions in both groups were delivered for 6 months. OUTCOME MEASURES: The primary outcome was cumulative incidence of arm lymphoedema defined in four ways (≥200ml,≥2cm,≥5%, and≥10% increase), which represent the difference in arm volume or circumference between the affected and healthy sides compared with the difference before surgery. Secondary outcomes included point prevalence of lymphoedema, change in arm volume difference, shoulder range of movement, quality of life and function.
RESULTS: Incidence rates were comparable between experimental and control groups at all follow-up measurements. Sixty months after surgery, the cumulative incidence rate for the≥200ml definition was 35% for the experimental group versus 29% for the control group (RR 0.89, 95% CI 0.51 to 1.54, p=0.45); for the≥2cm definition 35% versus 38% (RR 0.93, 95% CI 0.59 to 1.45, p=0.73); for the≥5% definition 68% versus 53% (RR 1.28, 95% CI 0.97 to 1.69, p=0.08) and for the≥10% definition 28% versus 24% (RR 1.18, 95% CI 0.66 to 2.10, p=0.57). The secondary outcomes were comparable between the groups at most assessment points.
CONCLUSION: Manual lymph drainage may not have a preventive effect on the development of breast cancer-related lymphoedema in the short and long term. TRIAL REGISTRATION: Netherlands Trial Register NTR 1055. [Devoogdt N, Geraerts I, Van Kampen M, De Vrieze T, Vos L, Neven P, Vergote I, Christiaens M-R, Thomis S, De Groef A (2018) Manual lymph drainage may not have a preventive effect on the development of breast cancer-related lymphoedema in the long term: a randomised trial. Journal of Physiotherapy 64: 245-254].
Copyright © 2018 Australian Physiotherapy Association. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Lymphoedema; Manual lymphatic drainage; Physical therapy; Prevention

Mesh:

Year:  2018        PMID: 30241913     DOI: 10.1016/j.jphys.2018.08.007

Source DB:  PubMed          Journal:  J Physiother        ISSN: 1836-9561            Impact factor:   7.000


  3 in total

1.  Interventions for Breast Cancer-Related Lymphedema: Clinical Practice Guideline From the Academy of Oncologic Physical Therapy of APTA.

Authors:  Claire Davies; Kimberly Levenhagen; Kathryn Ryans; Marisa Perdomo; Laura Gilchrist
Journal:  Phys Ther       Date:  2020-07-19

Review 2.  Conservative interventions and clinical outcome measures used in the perioperative rehabilitation of breast cancer patients undergoing mastectomy: a scoping review.

Authors:  Janny Mathieu; Catherine Daneau; Nadège Lemeunier; Annabelle Doyon; Andrée-Anne Marchand; Martin Descarreaux
Journal:  BMC Womens Health       Date:  2022-08-16       Impact factor: 2.742

3.  Manual lymphatic drainage for lymphedema in patients after breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Mining Liang; Qiongni Chen; Kanglin Peng; Lu Deng; Li He; Yongchao Hou; Yang Zhang; Jincai Guo; Zubing Mei; Lezhi Li
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.